Recommendations of the Second Indo-US Health Summit on Prevention and Control of Cardiovascular Disease among Asian Indians

Indian Heart Journal

Volumn 61, Issue 3, 2009, Pages 265-274

  Enas, Enas A ^a   Singh, Vibhuti ^b   Munjal, Y P ^c   Gupta, Rajeev ^d   Patel, Kiran C R ^e   Bhandari, Suman ^f   Agarwal, A K ^g,h   Joshi, Shashank R ^r   Misra, Anoop ^d   Prabhakaran, D ⁱ   Shah, Bela ^j   Reddy, Srinath ^k,l   Sharma, Brahma ^m,n   Trehan, Naresh ^o   Yavagal, S T ^p   Kasliwal, R R ^q  

^a Coronary Artery Disease in Asian Indians ^*  (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c Indian College of Physicians   (India)

^d FORTIS HOSPITAL   (India)

^e South Asian Health Foundation   (United Kingdom)

^f ESCORTS HEART INSTITUTE AND RESEARCH CENTRE   (India)

^g Association of Physicians of India   (India)

^h DR RAM MANOHAR LOHIA HOSPITAL   (India)

ⁱ Centre for Chronic Disease Control (CCDC)   (India)

^j INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^k PUBLIC HEALTH FOUNDATION OF INDIA   (India)

^l ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^m UNIVERSITY OF PITTSBURGH   (United States)

ⁿ AAPI CF   (United States)

^o Global Health MediCity   (India)

^p Indian College of Cardiology   (India)

^q INDRAPRASTHA APOLLO HOSPITAL   (India)

^r Apollo Hospital ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN; WARFARIN;

ACUTE CORONARY SYNDROME; ASIAN; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET SUPPLEMENTATION; DRUG MECHANISM; DYSLIPIDEMIA; HEALTH CARE; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH EDUCATION; HEALTH PROGRAM; HEALTH PROMOTION; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; INDIAN; LIFESTYLE MODIFICATION; MEDICAL RESEARCH; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PREVENTIVE MEDICINE; REVIEW; SCREENING TEST; WEIGHT CONTROL;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; HEALTH PROMOTION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; INDIA; MOTOR ACTIVITY; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; UNITED STATES;

EID: 73349123191     PISSN: 00194832     EISSN: 00194832     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Gupta R, Joshi P, Mohan V, Reddy KS, Yusuf S. Epidemiology and causation of coronary heart disease and stroke in India. Heart 2008;94:16-26.
2. Enas EA. Coronary artery disease epidemic in Indians: A cause for alarm and call for action. Indian Med Assoc 2000;98:694-5, 697-702.
3. Enas EA, Mehta J. Malignant coronary artery disease in young Asian Indians: Thoughts on pathogenesis, prevention, and treatment. Clin Cardiol 1995;18:131-135.
4. Enas EA. How to Beat the Heart Disease Epidemic among South Asians: A Prevention and Management Guide for Asian Indians and their Doctors. Downers Grove: Advanced Heart Lipid Clinic USA, 2007.
5. Enas EA, Chacko V, Senthilkumar A, Puthumana N, Mohan V. Elevated Lipoprotein(a) Risk Factor for Premature Vascular Disease in People With and Without Standard Risk Factors: A Review. Dis Mon 2006;52:5-50.
6. Forouhi NG, Sattar N, Tillin T, McKeigue PM, Chaturvedi N. Do known risk factors explain the higher coronary heart disease mortality in South Asian compared with European men? Prospective follow of the Southall and Brent studies, UK. Diabetologia 2006;49:2580-8.
7. Enas EA, Singh V, Munjal YP, Bhandari S, Yadave D, Manchanda S. Reducing the Burden Coronary Artery Disease in India: Challenges and opportunities. Indian Heart J 2008;60:161
8. Enas EA, Chacko V, Pazhoor SG, Chennikkara H, Devarapalli HP. Dyslipidemia in South patients. Curr Atheroscler Rep 2007;9:367-74.
9. Misra A, Khurana L. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab 2008;93:S9-30.
10. Lip GY, Barnett AH, Bradbury A, Cappuccio FP, Gill PS, Hughes E, Imray C, Jolly K, Patel K. Ethnicity and cardiovascular disease prevention in the United Kingdom: a practical approach to management. J Hum Hypertens 2007;21:183-211.
11. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-63.
12. Snehalatha C, Viswanathan V, Ramachandran A. Cutoff values for normal anthropometric variables in Asian Indian adults. Diabetes Care 2003;26:1380-4.
13. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL, Jr., Kaplan NM, O'Connor CM, O'Gara PT, Oparil S. Treatment of hypertension in the prevention and management of ischemic disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. 2007;115:2761-88.
14. Misra A , Chowbey P, Makkar B. Consensus statement for diagnosis of obesity, abdominal obesity, and metabolc syndrome, for Asian Indians and recomendations for physical activity, medical and surgical management. JAPI 2009;57:163-170.
15. Grundy SM. Primary prevention of coronary heart disease: Integrating risk assessment with intervention. Circulation 1999;100:988-998.
16. Graham I, Atar D, Borch-Johnsen K, Boysen G, Durrington PN. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007;28:2375-414.
17. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Ambrosioni E, Williams B. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.
18. Rosendorff C. Hypertension and coronary artery disease: a summary of the American Heart Association scientific statement. J Clin Hypertens (Greenwich) 2007;9:790-5.
19. Lopez V A, Franklin SS, Tang S, Wong ND. Coronary heart disease events preventable by control of blood pressure and lipids in US adults with hypertension. J Clin Hypertens (Greenwich) 2007;9:436-43.
20. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr., Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Jr., Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
21. Mohan V, Sandeep S, Deepa M, Gokulakrishnan K, Datta M, Deepa R. A diabetes risk score helps identify metabolic syndrome and cardiovascular risk in Indians - the Chennai Urban Rural Epidemiology Study (CURES-38). Diabetes Obes Metab 2007;9:337-43.
22. Enas EA, Mohan V, Deepa M, Farooq S, Pazhoor S, Chennikkara H. The Metabolic Syndrome and Dyslipidemia Among Asian Indians: A Population With High Rates of Diabetes and Premature Coronary Artery Disease. J Cardiometab Syndr 2007;2:267-275.
23. R. D, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, Liu K, Shea S, Szklo M, Bluemke DA, O'Leary DH, Tracy R, Watson K, Wong ND, Kronmal RA. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008;358:1336-45.
24. Budoff MJ, Nasir K, McClelland RL, Detrano R, Wong N, Blumenthal RS, Kondos G, Kronmal RA. Coronary calcium predicts events better with absolute calcium scores than age-sex-race/ethnicity percentiles: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2009;53:345-52.
25. Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Dolor RJ, Urbina E, Wenger NK. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. J Am Coll Cardiol 2007;49:1230-50.
26. Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol 2007;49:1753-62.
27. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-25.
28. Newman CB, Palmer G, Silbershatz H, Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol 2003;92:670-6.
29. Larosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H. Safety and Efficacy of Atorvastatin-Induced Very Low-Density Lipoprotein Cholesterol Levels in Patients With Coronary Heart Disease (a Post Hoc Analysis of the Treating to New Targets [TNT] Study). Am J Cardiol 2007;100:747-52.
30. Kostis JB, Breazna A, Deedwania PC, LaRosa JC. The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study. J Clin Hypertens (Greenwich) 2008;10:367-76.
31. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
32. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. Jama 2006;295:1556-65.
33. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. Jama 2004;291:1071-80.
34. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
35. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
36. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Prevention of and stroke events with atorvastatin in hypertensive patients who have average or lower-than cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
37. Stein EA. Statins and children: whom do we treat and when? Circulation 2007;116:594-5.
38. McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP, Hayman LL, Daniels SR. Drug therapy of high-risk lipid abnormalities in children and adolescents: a statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007;115:1948-67.
39. Shafiq N, Bhasin B, Pattanaik S, Pandhi P, Venkateshan SP, Singh M, Malhotra S. A analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia. Pharmacol Ther 2007;45:548-55.
40. Liu J, Sempos C, Donahue RP, Dorn J, Trevisan M, Grundy SM. Joint distribution of non LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diabetes Care 2005;28:1916-21.
41. Lu W, Resnick HE, Jablonski KA, Jones KL, Jain AK, Howard WJ, Robbins DC, Howard BV. Non HDL Cholesterol as a Predictor of Cardiovascular Disease in Type 2 Diabetes: The Strong Study. Diabetes Care 2003;26:16-23.
42. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. 2005;112:3375-83.
43. Ballantyne CM, Raichlen JS, Cain VA. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. J Am Coll Cardiol 2008;52:626-32.
44. Robinson JG. W, S., Smith BJ, Jacobson TA. Meta-analysis of the relationship between density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 2009;53:316-22.
45. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92.
46. Boden WE, O'Rourke R A, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS. Optimal Medical Therapy with or without PCI for Stable Coronary Disease. N Engl J Med 2007.
47. Jha P, Jacob B, Gajalakshmi V, Gupta PC, Dhingra N, Kumar R, Sinha DN, Dikshit RP, Parida DK, Kamadod R, Boreham J, Peto R. A Nationally Representative Case-Control Study of Smoking and Death in India. N Engl J Med 2008.
48. Gidding SS, Lichtenstein AH, Faith MS, Karpyn A, Mennella JA, Popkin B, Rowe J, Van Horn L, Whitsel L. Implementing American Heart Association pediatric and adult nutrition guidelines: a scientific statement from the American Heart Association Nutrition Committee of the council on nutrition, physical activity and metabolism, council on cardiovascular disease in the young, council on arteriosclerosis, thrombosis and vascular biology, council on cardiovascular nursing, council on epidemiology and prevention, and council for high blood pressure research. 2009;119:1161-75.
49. Enas EA, Senthilkumar A, Chennikkara H, Bjurlin MA. Prudent diet and preventive nutrition from pediatrics to geriatrics: current knowledge and practical recommendations. Indian Heart J 2003;55:310-38.
50. Misra A, Khurana L, Vikram NK, Goel A, Wasir JS. Metabolic syndrome in children: current issues and South Asian perspective. Nutrition 2007;23:895-910.
51. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA. AHA/ACC for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363